Stay updated on Pembrolizumab Post-ASCT in Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    Site-level revision notes show Revision: v3.4.2 with dates 2026-01-26 and 2026-02-12, replacing v3.4.1; this does not affect the study data or core content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-02-13T12:38:31.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    Revision updated from v3.4.0 to v3.4.1. No visible changes to study content or navigation.
    Difference
    0.1%
    Check dated 2026-02-05T17:19:47.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    30 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.3.4 and has removed Revision: v3.3.3, a minor metadata update that does not alter study details. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-15T03:03:36.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    Locations section added, listing California, Massachusetts, New York, and Texas under a single Locations heading; old state-specific location blocks replaced. HHS Vulnerability Disclosure link removed.
    Difference
    0.5%
    Check dated 2025-12-24T12:17:07.000Z thumbnail image
  6. Check
    81 days ago
    Change Detected
    Summary
    Added a note that publications are automatically filled in from PubMed and may not be about the study, and updated the revision to v3.3.2.
    Difference
    0.1%
    Check dated 2025-11-25T14:42:20.000Z thumbnail image
  7. Check
    88 days ago
    Change Detected
    Summary
    Removed the government funding status disclaimer from the page, an administrative banner that does not affect study content, eligibility, locations, or user actions. No substantive changes to the study data or navigation were made. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-18T07:25:11.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Post-ASCT in Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.